@article{ref1,
title="Long-Term Tolerability of Escitalopram in Korean Adolescents",
journal="Journal of the Korean Academy of Child and Adolescent Psychiatry",
year="2013",
author="Goo, Ae-Jin and Won, Eun-Kyung and Lee, Cheolsoon and Lee, Jong-Il and Jung, Hee-Yeon and Kim, Yeni",
volume="",
number="",
pages="207-212",
abstract="OBJECTIVES: We investigated the long-term tolerability of escitalopram in Korean adolescents. <br><br>METHODS: The subjects were 37 adolescents, who had been diagnosed with depressive disorder in accordance to DSM-IV. Clinical effectiveness was assessed by Clinical Global Impression-Improvement (CGI-I) scale at the final follow-up visit. Tolerability was assessed through a medical record of the reason for discontinuation of escitalopram and documented adverse events. <br><br>RESULTS: The mean duration of treatment was 78.1+/-89.5 days, and the mean dosage was 10.0+/-4.4mg/day. Out of the total 37 patients, two (5%) patients sustained use of escitalopram. Twelve patients (32.4%) discontinued use of escitalopram due to target symptom remission, and 23 patients (61.9%) due to insufficient efficacy. Six patients (16.2%) had at least one documented adverse event. However, no suicidal ideation or self-injurious behavior was reported. Significant differences in clinical symptom improvement efficacy were seen between the patients who were receiving escitalopram for less than 8 weeks (4.3%, 1/13) and those for more than 8 weeks (92.9%, 13/14). There was no significant difference between the tolerability of monotherapy compared to the concomitant use group. <br><br>CONCLUSION: The results of this study suggest that long-term use of escitalopram may result in superior efficacy than short-term use, and is tolerable in Korean adolescents with depression.<p /><p>Language: en</p>",
language="en",
issn="1225-729X",
doi="",
url="http://dx.doi.org/"
}